Clinical Trial ProgressThe company's focus on advancing its lead program, SL-325, towards the clinic as a potential first-in-class DR3 antagonist antibody for IBD treatment is a promising development.
Financial PerformanceThe announcement of 1Q25 results showed an EPS of ($0.27), which was better than both the analyst's estimate of ($0.40) and the consensus of ($0.28).
Preclinical DataPositive preclinical data for SL-325 was presented at the 20th Congress of ECCO in Inflammatory Bowel Diseases, highlighting its potential as a differentiated approach to current IBD treatments.